Axxcess Wealth Management LLC Has $4.44 Million Stock Holdings in Gilead Sciences, Inc. $GILD

Key Points

• Axxcess Wealth Management boosted its Gilead Sciences stake by 170.8% in the fourth quarter, ending with 36,202 shares valued at about $4.44 million. The filing also noted that institutional investors and hedge funds own 83.67% of Gilead’s stock.
• Gilead reported better-than-expected quarterly results, posting EPS of $2.03 versus estimates of $1.91 and revenue of $6.96 billion versus expectations of $6.91 billion. The company also raised attention with a $0.82 quarterly dividend, equal to a 2.4% yield.
• The company’s recent pipeline and business updates were favorable, including FDA accelerated approval for Hepcludex in hepatitis delta virus, a positive CHMP opinion for Trodelvy in Europe, and completion of the Tubulis acquisition to strengthen its oncology portfolio.

Axxcess Wealth Management LLC lifted its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 170.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 36,202 shares of the biopharmaceutical company's stock after acquiring an additional 22,831 shares during the quarter. Axxcess Wealth Management LLC's holdings in Gilead Sciences were worth $4,443,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of GILD. Ares Financial Consulting LLC acquired a new position in shares of Gilead Sciences in the fourth quarter worth $28,000. Financial Consulate Inc. increased its position in Gilead Sciences by 85.8% during the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 109 shares during the last quarter. North Star Investment Management Corp. increased its position in Gilead Sciences by 54.8% during the fourth quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company's stock worth $30,000 after buying an additional 86 shares during the last quarter. MTM Investment Management LLC increased its position in Gilead Sciences by 176.0% during the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company's stock worth $31,000 after buying an additional 176 shares during the last quarter. Finally, BOCHK Asset Management Ltd acquired a new position in Gilead Sciences during the fourth quarter worth $31,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Trading Up 3.0%

Shares of NASDAQ:GILD opened at $134.36 on Friday. The company has a market cap of $166.82 billion, a P/E ratio of 18.31 and a beta of 0.31. The stock's 50-day moving average is $136.27 and its 200-day moving average is $133.65. Gilead Sciences, Inc. has a 52-week low of $104.46 and a 52-week high of $157.29. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.91 by $0.12. The company had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The firm's revenue was up 4.4% compared to the same quarter last year. During the same period last year, the business posted $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050--0.650 EPS. Equities research analysts predict that Gilead Sciences, Inc. will post -0.79 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be paid a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.4%. The ex-dividend date is Monday, June 15th. Gilead Sciences's dividend payout ratio (DPR) is presently 44.69%.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: The U.S. FDA granted accelerated approval to Hepcludex (bulevirtide-gmod) for chronic hepatitis delta virus (HDV), making it the first and only approved treatment in the U.S. for this rare and serious liver disease. That opens a new commercial opportunity in a high-unmet-need market. Article Title
• Positive Sentiment: Gilead also received a CHMP positive opinion in Europe for Trodelvy in first-line metastatic triple-negative breast cancer, supporting broader international adoption of one of its key oncology products. Article Title
• Positive Sentiment: Gilead completed its Tubulis acquisition, adding next-generation antibody-drug conjugate assets and strengthening its oncology pipeline. Article Title
• Positive Sentiment: Analysts at Zacks Research raised near-term EPS estimates for some periods and maintained strong longer-term profit expectations, which can support investor confidence in Gilead’s earnings outlook. Article Title
• Neutral Sentiment: Gilead announced a renewed collaboration with the World Health Organization to help eliminate visceral leishmaniasis, a public-health initiative that is strategically positive but likely not an immediate stock driver. Article Title
• Negative Sentiment: Some analyst updates trimmed certain 2026–2028 earnings estimates, which may temper enthusiasm around the stock’s longer-term growth rate, even as recent product news remains favorable. Article Title

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $132.27, for a total value of $396,810.00. Following the completion of the sale, the chief financial officer owned 173,191 shares in the company, valued at approximately $22,907,973.57. This trade represents a 1.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O'day sold 10,000 shares of the stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $129.16, for a total transaction of $1,291,600.00. Following the completion of the sale, the chief executive officer owned 632,567 shares of the company's stock, valued at approximately $81,702,353.72. The trade was a 1.56% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 63,000 shares of company stock worth $8,523,570. Company insiders own 0.30% of the company's stock.

Analysts Set New Price Targets

GILD has been the topic of several analyst reports. Maxim Group raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $165.00 target price on the stock in a research report on Wednesday. Argus increased their target price on shares of Gilead Sciences from $135.00 to $165.00 and gave the stock a "buy" rating in a research report on Thursday, February 19th. Jefferies Financial Group initiated coverage on shares of Gilead Sciences in a research report on Tuesday, March 10th. They set a "buy" rating and a $180.00 target price on the stock. Sanford C. Bernstein reissued an "outperform" rating and set a $160.00 target price on shares of Gilead Sciences in a research report on Wednesday, February 11th. Finally, Oppenheimer increased their target price on shares of Gilead Sciences from $128.00 to $165.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 11th. Twenty-five research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $156.93.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.